In summary, we have reported the multiple functionaliza-
tion20 of the pyrazine scaffold using TMPMgCl·LiCl (2a)
and TMPZnCl·LiCl (2b) as effective bases and reported a
nine-step synthesis of the natural product coelenterazine (1).
Further extensions and applications of this method are
currently underway in our laboratories.
Scheme 5
.
Synthesis of 3-(4-Methoxyphenyl)-2-oxopropanal
(26) and Coelenterazine (1)
Acknowledgment. We thank the Fonds der Chemischen
Industrie, the Deutsche Forschungsgemeinschaft (DFG), and
the European Research Council (ERC) for financial support.
We also thank Evonik GmbH, BASF AG, W.C. Heraeus
GmbH, and Chemetall GmbH for the generous gift of
chemicals.
Supporting Information Available: Experimental pro-
cedures and analytical data. This material is available free
25 °C for 1 h affords the corresponding acetoxy R-keto
aldehyde 26 in 70% yield.19 Finally, the condensation of the
1,2-dicarbonyl derivative 26 with coelenteramine (22) pro-
vides the bioluminescent natural product coelenterazine (1)
in 64% yield.19
OL901275N
(17) Lehr, M. J. Med. Chem. 1997, 40, 3381.
(18) Metzger, A.; Schade, M. A.; Knochel, P. Org. Lett. 2008, 10, 1107.
(19) Chen, F.-Q.; Zheng, J.-L.; Hirano, T.; Niwa, H.; Ohmiya, Y.;
Ohashi, M. J. Chem. Soc., Perkin Trans. 1 1995, 17, 2129.
(13) (a) Kishi, Y.; Tanino, H.; Goto, T. Tetrahedron Lett. 1972, 27,
2747. (b) Inoue, S.; Sugiura, S.; Kakoi, H.; Hashizume, K.; Goto, T.; Iio,
H. Chem. Lett. 1975, 141. (c) Inoue, S.; Kakoi, H.; Murata, M.; Goto, T.;
Shimomura, O. Chem. Lett. 1979, 249. (d) Shimomura, O.; Johnson, F. H.;
Morise, H. Biochemistry 1974, 13, 3278. (e) Shimomura, O.; Musicki, B.;
Kishi, Y. Biochem. J. 1989, 261, 913. (f) Adamczyk, M.; Rao Akireddy,
S.; Johnson, D. D.; Mattingly, P. G.; Pan, Y.; Reddy, R. E. Tetrahedron
2003, 59, 8129. (g) Gonzalez-Trueba, G.; Paradisi, C.; Zoratti, M. Anal.
Biochem. 1996, 240, 308. (h) Jones, K.; Keenan, M.; Hibbert, F. Synlett
1996, 509. (i) Keenan, M.; Jones, K.; Hibbert, F. Chem. Commun. 1997, 3,
323. (j) Kakoi, H Chem. Pharm. Bull. 2002, 50, 301.
(20) Procedure for the synthesis of 3,5-dichloro-2-(4-methoxyphe-
nyl)pyrazine (10a): A dry and argon flushed 50 mL Schlenk flask, equipped
with a magnetic stirrer and a septum, was charged with 2,6-dichloropyrazine
(8) (1,49 g, 10.0 mmol) dissolved in THF (10 mL). A solution of
TMPZnCl·LiCl (2b) (1.4 M in THF, 7.9 mL, 11.1 mmol) at 25 °C was
then added, and the reaction mixture was stirred at this temperature for 30
min. Pd(dba)2 (113 mg, 2 mol %) and P(o-furyl)3 (93 mg, 4 mol %)
dissolved in THF (5 mL) and mixed with 4-iodoanisole (3.04 g, 13 mmol,
1.3 equiv) were then transferred via cannula to the reaction mixture. The
resulting mixture was stirred at 65 °C for 1 h, quenched with a sat. aq.
NH4Cl solution (100 mL), extracted with diethyl ether (3 × 100 mL), and
dried over anhydrous Na2SO4. After filtration, the solvent was evaporated
in vacuo. Purification by flash chromatography (CH2Cl2/pentane 1:3)
furnished the compound 10a (2.18 g, 86% yield) as a colourless solid.
(14) Negishi, E.; Bagheri, V.; Chatterjee, S.; Luo, F. T.; Miller, J. A.;
Stoll, A. T. Tetrahedron Lett. 1983, 24, 5181.
(15) Turck, A.; Mojovic, L.; Que´guiner, G. Synthesis 1988, 881.
(16) Burton, M.; De Tollenaere, C.; Dussart, F.; Marchand, C.; Rees,
J. F.; Marchand-Brynaert, J. Synthesis 2001, 768.
Org. Lett., Vol. 11, No. 15, 2009
3409